Novartis Seeks Nod for Covid Drug in U.S. Before Final Test (1)

Jan. 12, 2022, 2:55 PM

Novartis AG will seek to bring its experimental Covid-19 drug to patients without waiting for results from a large clinical trial, Chief Executive Officer Vas Narasimhan said, potentially giving governments another option to battle the latest pandemic onslaught.

The Swiss pharma giant aims to request an emergency-use authorization for the compound, ensovibep, with the U.S. Food and Drug Administration within the next month, Narasimhan said in an interview. A larger study to confirm promising data that emerged this week could be finished by the second half of the year, he said.

“Our aspiration at the moment is to see if ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.